Selected article for: "RBD region and SARS RBD sequence"

Author: Cecylia S. Lupala; Xuanxuan Li; Jian Lei; Hong Chen; Jianxun Qi; Haiguang Liu; Xiao-dong Su
Title: Computational simulations reveal the binding dynamics between human ACE2 and the receptor binding domain of SARS-CoV-2 spike protein
  • Document date: 2020_3_27
  • ID: kifqgskc_29
    Snippet: the key residues at the binding interface were identified and summarized in Table 2 for the three representative models (see Figure 2 ). Majority of these residues are conserved for these three models, except that the model#1 (Figure 2a ) has additional contacts to the ACE2 from residues in the L 67 region (highlighted with green color in Table 2 ). As shown in Figure 2 , the L 67 remained in the starting position for the other two representative.....
    Document: the key residues at the binding interface were identified and summarized in Table 2 for the three representative models (see Figure 2 ). Majority of these residues are conserved for these three models, except that the model#1 (Figure 2a ) has additional contacts to the ACE2 from residues in the L 67 region (highlighted with green color in Table 2 ). As shown in Figure 2 , the L 67 remained in the starting position for the other two representative models (Figure 2b,c) . The same simulations were carried out for the SARS-RBD/ACE2 complex, serving as a comparative system. Interestingly, the SARS-RBD counterpart of the L 67 in CoV2-RBD did not form close contacts with the ACE2 in three simulations. It is worthwhile to mention that the sequence identity between CoV2-RBD and SARS-RBD is low in this loop region, suggesting the loop region might be partially responsible for the difference in the receptor binding.

    Search related documents:
    Co phrase search for related documents
    • additional contact and green color: 1
    • additional contact and SARS RBD: 1
    • binding interface and close contact: 1
    • binding interface and key residue: 1, 2, 3, 4, 5
    • binding interface and loop region: 1, 2, 3, 4
    • binding interface and receptor bind: 1, 2, 3, 4, 5, 6, 7
    • binding interface and SARS RBD: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • binding interface and sequence identity: 1, 2, 3, 4, 5, 6, 7
    • binding interface key residue and key residue: 1
    • binding interface key residue and SARS RBD: 1
    • close contact and receptor bind: 1
    • close contact and SARS RBD: 1, 2, 3, 4, 5, 6
    • key residue and loop region: 1
    • key residue and residue majority: 1
    • key residue and SARS RBD: 1, 2, 3, 4, 5, 6, 7
    • key residue and sequence identity: 1, 2
    • loop region and SARS RBD: 1, 2, 3
    • loop region and sequence identity: 1, 2
    • receptor bind and SARS RBD: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25